News
RNA
31.82
+2.48%
0.77
AVIDITY BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Promising Advancements and Strategic Growth: A Buy Rating for Avidity Biosciences
TipRanks · 1d ago
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga · 2d ago
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Benzinga · 2d ago
Avidity Biosciences Initiated at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Avidity Biosciences Price Target Announced at $72.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $72
Benzinga · 2d ago
Avidity Biosciences initiated with a Buy at H.C. Wainwright
TipRanks · 2d ago
AVIDITY BIOSCIENCES INC <RNA.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $72
Reuters · 2d ago
U.S. RESEARCH ROUNDUP-Ares Management, Evercore, Tompkins Financial
Reuters · 2d ago
Avidity Biosciences CEO Boyce sells 31,855 common shares
TipRanks · 2d ago
Jefferies healthcare analyst holds an analyst/industry conference call
TipRanks · 3d ago
PepGen stock craters 35% on FDA clinical hold
Seeking Alpha · 6d ago
Weekly Report: what happened at RNA last week (1209-1213)?
Weekly Report · 6d ago
Avidity Biosciences Becomes Oversold (RNA)
NASDAQ · 12/13 17:44
3 Best Stocks to Buy Now, 12/13/2024, According to Top Analysts 
TipRanks · 12/13 11:14
Avidity Biosciences (RNA) Receives a Buy from TD Cowen
TipRanks · 12/13 04:25
Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
Seeking Alpha · 12/11 14:25
Weekly Report: what happened at RNA last week (1202-1206)?
Weekly Report · 12/09 10:47
Weekly Report: what happened at RNA last week (1125-1129)?
Weekly Report · 12/02 10:47
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Avidity Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.